Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL755912 | 0.81 | BRD4 (0.47) | BRD4 | |
| SCHEMBL2843725 | 0.78 | BRD4 (0.31) | BRD4 | |
| SCHEMBL2843728 | 0.78 | BRD4 (0.31) | BRD4 | |
| SCHEMBL30869620 | 0.71 | AHR (0.38) | — | |
| SCHEMBL30869424 | 0.71 | AHR (0.38) | — | |
| SCHEMBL1252487 | 0.71 | KDM4E (0.36) | — | |
| Bromide SCHEMBL1254216 | 0.70 | KDM4E (0.35) | — | |
| Bromide SCHEMBL1254215 | 0.69 | KDM4E (0.35) | — | |
| SCHEMBL3376772 | 0.68 | PGR (0.38) | — | |
| SCHEMBL2840423 | 0.65 | AKR1B1 (0.34) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156578-A1 | 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents | DEBIOPHARM INTERNATIONAL SA (CH) | 2009-06-18 | — | — | US | disclosed |
| US-20090156578-A1 | 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents | DEBIOPHARM INTERNATIONAL SA (CH) | 2009-06-18 | — | — | US | disclosed |
| US-20090156578-A1 | 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents | DEBIOPHARM INTERNATIONAL SA (CH) | 2009-06-18 | — | — | US | disclosed |
| WO-2007067416-A2 | HETEROCYCLYLACRYLAMIDE COMPOUNDS AS FABI INHIBITORS AND ANTIBACTERIAL AGENTS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156578-A1 | 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents | GAA, TFPI, DBI | BRD4 168/4885PTGES 2662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.